Abstract:BACKGROUND: Reduced plasma tryptophan occurs in depression and somatization. Induction of indoleamine 2,3-dioxygenase (IDO) with consequent synthesis of tryptophan catabolites (TRYCATs) and lowered tryptophan are associated with the onset of depression in the puerperium and during interferon-alpha treatment. Depression is accompanied by lowered kynurenic acid, a neuroprotectant, or increased kynurenine, a neurotoxic TRYCAT. AIMS AND METHODS: To examine plasma tryptophan; kynurenine; kynurenic acid; the kynurenine / tryptophan (KY/TRP) ratio, indicating IDO activity; and the kynurenine / kynurenic acid (KY/KA) ratio, indicating kynurenine aminotransferase (KAT) activity, in somatization; depression; somatization + depression; and controls. Illness severity is measured by the Somatic Symptom Index (SSI), the Screening for Somatoform Symptoms (SOMS), and the Beck Depression Inventory (BDI). RESULTS: Tryptophan is significantly lower in patients than in controls and lower in somatization than in depression. KY/TRP is significantly increased in somatization. Kynurenic acid is significantly lower in patients than in controls, and lower in somatization than in depression. KY/KA is significantly higher in somatization and somatization + depression than in depression and controls. There are significant correlations between the severity of somatization, but not depression, and KY/TRP and KY/KA (positive) and tryptophan (negative). Kynurenine and kynurenic acid are significantly correlated in controls, somatization + depression, and depression, but not in somatization. CONCLUSIONS: Somatization is characterized by increased IDO activity and disorders in KAT activity and an increased neurotoxic potential. The TRYCAT pathway may play a role in the pathophysiology of somatizing and "psychosomatic" symptoms through effects on pain, gut motility, the autonomic nervous system, peripheral NMDA receptors, etc. Even more, biological disorders, such as aberrations in the TRYCAT pathway, which are considered to be a hallmark for depression, are in fact attributable to somatization rather than to depression per se. Future research in depression on the TRYCAT pathway should always control for the possible effects of somatization.

Biological underpinnings of the commonalities in depression, somatization, and Chronic Fatigue Syndrome.

Biological phenotypes underpin the physio-somatic symptoms of somatization, depression, and chronic fatigue syndrome.

Dysfunction in Serotonergic and Noradrenergic Systems and Somatic Symptoms in Psychiatric Disorders

An intriguing and hitherto unexplained co-occurrence: Depression and chronic fatigue syndrome are manifestations of shared inflammatory, oxidative and nitrosative (IO&NS) pathways

Inflammatory and Oxidative and Nitrosative Stress Pathways Underpinning Chronic Fatigue, Somatization and Psychosomatic Symptoms

Biological mechanisms of somatic symptoms in depressive disorder

Psychobiological Aspects of Somatoform Disorders: Contributions of Monoaminergic Transmitter Systems.

ME/CFS and Long COVID share similar symptoms and biological abnormalities: road map to the literature

"Functional" or "psychosomatic" Symptoms, E.G. A Flu-Like Malaise, Aches and Pain and Fatigue, Are Major Features of Major and in Particular of Melancholic Depression

Inflammation-Related Disorders in the Tryptophan Catabolite Pathway in Depression and Somatization

Myalgic Encephalomyelitis/chronic Fatigue Syndrome: from Pathophysiological Insights to Novel Therapeutic Opportunities.

In Schizophrenia, Chronic Fatigue Syndrome- and Fibromyalgia-Like Symptoms Are Driven by Breakdown of the Paracellular Pathway with Increased Zonulin and Immune Activation-Associated Neurotoxicity

Suppressed immune and metabolic responses to intestinal damage-associated microbial translocation in myalgic encephalomyelitis/chronic fatigue syndrome

Somatization, but not depression, is characterized by disorders in the tryptophan catabolite (TRYCAT) pathway, indicating increased indoleamine 2,3-dioxygenase and lowered kynurenine aminotransferase activity.

Shared microglial mechanisms underpinning depression and chronic fatigue syndrome and their comorbidities

Aberrations in the Cross-Talks Among Redox, Nuclear Factor-kappa B, and Wnt/beta-Catenin Pathway Signaling Underpin Myalgic Encephalomyelitis and Chronic Fatigue Syndrome

Diagnostic classifications in depression and somatization should include biomarkers, such as disorders in the tryptophan catabolite (TRYCAT) pathway.

Depression and Sickness Behavior Are Janus-faced Responses to Shared Inflammatory Pathways

In myalgic encephalomyelitis/chronic fatigue syndrome, increased autoimmune activity against 5-HT is associated with immuno-inflammatory pathways and bacterial translocation.

Inflammatory and Oxidative and Nitrosative Stress Cascades As New Drug Targets in Myalgic Encephalomyelitis and Chronic Fatigue Syndrome.

Aberrations in the Cross-Talks Among Redox, Nuclear Factor-κB, and Wnt/β-Catenin Pathway Signaling Underpin Myalgic Encephalomyelitis and Chronic Fatigue Syndrome